COMPARISON OF THREE CHEMOTHERAPY REGIMENS TO THE DECREASE IN LEUKOCYTES AND THE INCIDENCE RATE OF NEUTROPENIA IN PATIENTS WITH NASOPHARYNGEAL CANCER AT DR. HASAN SADIKIN GENERAL HOSPITAL BANDUNG

Nadiya Nurul Afifah; Pratiwi; Keri Lestari; Ajeng Diantini

doi:10.22159/ajpcr.2017.v10s2.20774

Authors

Nadiya Nurul Afifah Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia.
Pratiwi Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia.
Keri Lestari Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia.
Ajeng Diantini Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10s2.20774

Keywords:

Nasopharyngeal cancer, Leukocyte, Neutropenia, Cisplatin, Cisplatin5-fluorouracil, Carboplatinpaclitaxel

Abstract

Objective: Nasopharyngeal cancer is the ninth most common cancer in Indonesia. The death of cancer patients is not only caused by cancer itself, but also several other factors such as the side effects of chemotherapy. Some side effects that occurred are decrease in leukocytes and incidence of neutropenia. Neutropenia is the highest hematological toxicity caused by chemotherapy treatment which has final manifestation is death from systemic infection. The purpose of this study is to compare three chemotherapy regimens in causing a decrease in leukocytes and the incidence of neutropenia in the patients with nasopharyngeal cancer in RSUP. Dr. Hasan Sadikin Bandung.

Methods: The three chemotherapy regimens compared in this study are cisplatin, cisplatin/5-fluorouracil (5-FU), and carboplatin/paclitaxel. This research is an analytic observational study with retrospective data collection and cross-sectional analytic design. The data were obtained from the medical records of inpatients with nasopharyngeal cancer during January-December 2015; total data 86 nasopharyngeal carcinoma patient[s] (>18 years old, female and male) data had been analyzed in this study.

Results: The percentage of neutropenia incidence in cisplatin regimen is 8.3%, in cisplatin/5-FU is 14.3%, and in carboplatin/ paclitaxel is 18.6%.

Conclusion: The results showed that there are no significant differences (p>0.05) in the three regimens in causing the reduction of leukocyte (p=0.327) and the average of absolute neutrophil count (p=0.240).

Downloads

Download data is not yet available.

References

World Health Organization (WHO); 2015. Cancer Fact Sheet. Available from: http://www.who.int/cancer/en/. [Last visited on 2015 Oct 03].

Pusat Kanker Nasional; 2009. Kemoterapi. Available from: http://www. dharmais.co.id/index.php/kemoterapi.html. [Last visited on 2015 Sep 20].

Nafriadi, Ganiswara SG. Farmakologi dan Terapi Edisi V - Antikanker. Jakarta: FKUI Press; 2007. p. 732-3.

Findlay GP, Goodwin AP, Protopapa K, Smith NC, Mason M. Knowing the Risk - A Review of the Peri-Operative Care of Surgical Patients. National Confidential Enquiry Patients Outcome and Death. United Kingdom; 2011

Friese RN, Christopher R. Chemotherapy-induced neutropenia: Important new data to guide nursing assessment and management. Adv Stud Nur Cancer Ther Support Care 2006;4:21-2.

Rosary S, Ambara SH. Penggunaan granulocyte colony-stimulating factor pada pasien tumor padat yang mengalami neutropenia. Ser Pediatri 2010;11:428-9.

American Cancer Society. Cancer Facts and Figures. Atlanta, Ga: American Cancer Society; 2015.

Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, et al. Treatment for metastetic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2011;128:70-85.

Paula G. Understanding Bone Metastases: When Cancer Spreads to the Bones; 2016. Available from: https://www.urmc.rochester.edu/ Encyclopedia/content.aspx?ContentTypeID=34&ContentID=25952-1. [Last visited on 2016 Mar 11].

Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni E, Olivetto E, et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. Oncol Rep 2013;29:1285-92.

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Bri J Cancer 2011;105:360-5.

Zhingou L, Chang J, Gou Y, Yu H, Lu F, Wu X, et al. Continuous infusion of 5-FU with split-dose cisplatin: An effective treatment for advanced squamous carcinoma of the head and neck. Clinical Investigative Med 2011;34. DOI: org/10.25011/cim.v34i1.14907.